The recent article by Morley et al provided for highly interesting and thought stimulating reading (1) . A significant co-relationship EXISTS between soluble TNF-alpha receptor1 (sTNFr1) levels and the evolution and progression of a number of different psychiatric disorders.
A significant association has been seen between sTNFr1 levels and the cognitive/ affective aspect of depression (2) . This is especially more pronounced in patients with coexisting comorbidities such as congestive heart failure. Higher levels are also noticed in patients with depression secondary to "posttraumatic stress disorder" (3) . A significant association is also seen between the age of the patients with major depression and the corresponding sTNFr1 levels. Similarly, elevated sTNFr1 levels have been noted in patients with bipolar disorder. Barbosa et al in a recent study have shown a significant impact of the duration of bipolar disorder on sTNFr1 levels (4). Simultaneous up-regulation of leptin expression is seen in these patients (5) . Interestingly, serum sTNFr1 levels in bipolar patients with frank manic symptoms are much higher than in bipolar patients with euthymia. A similar relationship has been noted in patients with underlying obsessive compulsive disorder. For instance, the severity of compulsive symptoms such as repetitive hand washing bears a close association with serum sTNFr1 levels (6) .
Similarly, elevated sTNFr1 levels in the CSF have been noted in patients with Alzheimer's disease. A significant association has seen between CSF sTNFr1 levels and CSF TNF-α converting enzyme (TACE) levels (7). Similar elevations have been noted in patients with "mild cognitive impairment". A significant association is also seen between CSF levels of sTNFr1 and CSF levels of tau as well as Aβ 40 in these patients (8) . The risk of progression from "mild cognitive impairment" to frank Alzheimer's disease is significantly accentuated with up-regulation if serum sTNFr1 expression (9) . Not surprisingly, a significant association is seen between CSF sTNFr1 levels and β-site APP-cleaving enzyme 1 activity in these patients (10) . A close association also exists between serum sTNFr1 levels and schizophrenia. Resistance to therapeutic intervention is more likely in those with comparatively higher sTNFr1 levels (11) .
Similar elevation in sTNFr1 levels has been noted in patients with certain neurological disorders such as Parkinson's disease (12) . The above examples further corroborate the fact that disturbances in inflammatory processes involving sTNFr1contribute to the evolution and progression of a number of psychiatric disorders.
